Spin, Scale, Dominate: The Management Play Making Waves

Some companies soar on hype. Others rise on fundamentals.

This one surged 94% thanks to a smart structural play: managing spin-offs under long-term agreements while keeping expenses lean.

With a second deal now secured, and on nearly identical terms to its first, the business is quietly turning into a recurring revenue machine.

U.S. stocks ended mixed Monday as surging AI stocks lifted the Nasdaq and the S&P 500, while rate-cut concerns and losses in blue-chip stocks dragged the Dow.

Kimberly-Clark (NYSE: KMB) is trading the baby wipes for Band-Aids with a blockbuster $40 billion plan to buy Kenvue, the Johnson & Johnson spinoff behind Tylenol, Listerine, and Neutrogena.

The move turns a household goods maker into a consumer health titan overnight.

It’s a smart way to merge comfort and care - the products you grab when you sneeze with the ones you reach for when you're hurt.

You can already imagine a bathroom shelf stocked with products from a single brand, from tissues to treatments.

The Plot Behind the Price Tag

Kenvue has been in the headlines for all the wrong reasons lately, with lawsuits and political heat surrounding Tylenol and baby powder.

But Kimberly-Clark clearly sees what’s beneath the noise: global reach, steady cash, and timeless brands people trust when it counts.

That’s not a risky gamble; it’s a brand rehab opportunity waiting to print profits. The long-term play is about owning every aisle that matters — from baby care to self-care.

The Future Feels Personal

If this deal closes, Kimberly-Clark won’t just be selling paper goods; it’ll be selling peace of mind. A single company blending hygiene, health, and habit.

And if you ever wondered which brand could transition seamlessly from the nursery to the medicine cabinet without missing a beat, you've just found your answer, and it comes with a $40 billion price tag.

Amazon (NASDAQ: AMZN) just landed a seven-year, $38 billion deal with OpenAI, giving the ChatGPT maker access to AWS’s army of Nvidia chips.

It’s the kind of win that turns skeptics into believers overnight.

This isn’t a small side gig. It’s a full-blown reset for Amazon’s cloud dominance, right when everyone thought Microsoft and Google had locked the door.

From Retail To Reinvention

AWS now powers the biggest AI brand on earth, which makes this partnership more than just bragging rights.

It’s proof that Amazon’s infrastructure muscle still runs deeper than most realize.

Every new AI model needs somewhere to live, and Amazon just built the penthouse. You can bet this deal will echo across data centers, chip orders, and boardrooms from here to 2030.

The Empire Reboots

For Amazon, this is more than just business; it’s a matter of reputation recovery. The deal repositions AWS as the go-to home for AI innovation and locks in years of high-margin cloud revenue.

This partnership doesn’t just make Amazon a player in AI; it makes it the power grid. Every company pursuing artificial intelligence will eventually rely on AWS, whether they like it or not.

And if you’re paying attention, you can already feel the shift; Amazon’s no longer competing for the future, it’s quietly becoming the infrastructure that defines it.

He’s been trading full-time for more than 30 years.

And there’s one tool he trusts above all others.

It’s his #1 indicator — a clear, reliable signal that’s helped him find major opportunities long before the crowd.

It’s not complicated. It’s not technical. And it’s not sold anywhere.

This is the same signal that’s guided him through every bull and bear market.

Now, for the first time, he’s giving you free access to it — along with a short guide explaining how it works.

[Get your free copy now]

Pfizer (NYSE: PFE) isn’t just chasing new drugs; it’s fighting for a comeback story.

The company has filed its second lawsuit to stop Novo Nordisk from snatching biotech firm Metsera, a rising star in obesity treatments.

It’s more than corporate sparring as this is Pfizer’s biggest swing at reclaiming relevance after its COVID-era profits vanished.

The company views Metsera as its key to a market that could revolutionize modern healthcare and redefine its own identity.

The Race for the Billion-Dollar Cure

Metsera is developing the next generation of obesity drugs that could rival Wegovy and Zepbound.

For Pfizer, owning that science could mean fresh momentum in a space currently ruled by rivals.

The stakes are massive, and the tone feels personal. You can sense Pfizer’s urgency to prove it still knows how to lead, not just litigate.

The Shot at Redemption

If Pfizer wins, it gets more than a pipeline it gets a new purpose.

The deal would mark a turn from pandemic fatigue to a fight for dominance in the world’s most profitable health frontier.

Pfizer isn’t just trying to fill revenue gaps anymore; it’s trying to matter again in a space reshaping medicine itself.

You can see the company throwing everything at this moment, because missing it could mean sitting out the next era of pharma entirely.

👉 Click here to get our closing report to your cell for free!

Resolute Holdings Management [RHLD] $143.13 (+94.31%)

Resolute Holdings rose after securing a new management deal with Husky Technologies, expanding its fee-generating model and reinforcing its position in the post-spinoff CompoSecure structure.

Terns Pharmaceuticals Inc [TERN] $14.03 (+69.85%)

Terns surged after its CML drug TERN-701 was selected for an oral presentation at ASH, with early data showing double the MMR rates of competing therapies.

Cipher Mining Inc [CIFR] $22.76 (+22.04%)

Cipher Mining soared after unveiling a $5.5 billion, 15-year AI infrastructure deal with AWS, marking a major pivot beyond crypto mining.

Uniqure N.V. [QURE] $34.29 (-49.34%)

UniQure plunged nearly 50% after the FDA unexpectedly backtracked on earlier guidance, casting doubt on the approval path for its Huntington’s gene therapy.

Alvotech [ALVO] $5.03 (-34.25%)

Alvotech sank further after the FDA rejected its biosimilar candidate for Simponi due to manufacturing issues, prompting a sharp revenue downgrade.

Sable Offshore Corp [SOC] $7.26 (-30.64%)

Sable Offshore tumbled to all-time lows after announcing a dilutive $225 million equity raise tied to a costly loan extension with Exxon Mobil.

Some stocks don’t just rise — they explode.

Market experts have narrowed down the field to 5 exceptional companies poised for strong upside potential in the coming months.

These picks come from deep analysis of earnings strength, market momentum, and institutional demand — factors that have historically led to triple-digit returns.

Previous reports from this research team have uncovered stocks that delivered +175%, +498%, even +673%.¹

Now, the latest report reveals five new opportunities — free to access, but only for a limited time.

[Unlock the 5 Stocks Set to Double – Free Until Midnight]

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.